A mechanism triggered by the activation of two specific proteins called JAK2 and STAT3 was found to contribute to the…
Articles by Alice Melão, MSc
A new mobile app called PF Health has been launched to help patients with pulmonary fibrosis track their symptoms and…
Galapagos is planning to launch a Phase 2 clinical trial for its treatment candidate GLPG1205 in patients with idiopathic…
The patientMpower digital healthcare app now offers a “share” tool that allows patients with pulmonary fibrosis and like conditions…
A pulmonologist’s characteristics — such as the nature of the practice and previous treatment experience — can influence when anti-fibrotic therapy…
PBI-4050, Prometic Life Sciences’ treatment candidate, can prevent lung fibrosis progression in patients with idiopathic pulmonary fibrosis (IPF)…
At the 2nd Annual IPF Summit in San Francisco this summer, academic and biopharma experts in idiopathic pulmonary…
The University of Virginia recently launched the Fibrosis Initiative, a platform intended to support and mobilize researchers to collaborate…
AdAlta has changed the structure of its lead therapy candidate for AD-114, for the treatment of pulmonary fibrosis.
A lung-scarring disease that affects preterm infants has a tissue repair signaling problem seen in idiopathic pulmonary fibrosis, Vanderbilt University…